Related references
Note: Only part of the references are listed.DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine
Jerome Moreaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
B. A. Walker et al.
LEUKEMIA (2014)
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
J. A. Oyer et al.
LEUKEMIA (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Kyle D. Konze et al.
ACS CHEMICAL BIOLOGY (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
Martin F. Kaiser et al.
BLOOD (2013)
NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
Zheng Huang et al.
CANCER RESEARCH (2013)
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Shivani Garapaty-Rao et al.
CHEMISTRY & BIOLOGY (2013)
Overexpression of MMSET in endometrial cancer: A clinicopathologic study
Min Xiao et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Irfan A. Asangani et al.
MOLECULAR CELL (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
Jacob D. Jaffe et al.
NATURE GENETICS (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer
T. Ezponda et al.
ONCOGENE (2013)
Overexpression of MMSET is Correlation with Poor Prognosis in Hepatocellular Carcinoma
Peng Zhou et al.
PATHOLOGY & ONCOLOGY RESEARCH (2013)
Epigenetics of the antibody response
Guideng Li et al.
TRENDS IN IMMUNOLOGY (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
Amir A. Toor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
Hsing-Chen Tsai et al.
CANCER CELL (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2012)
Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jerome Moreaux et al.
MOLECULAR CANCER THERAPEUTICS (2012)
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K. D. Boyd et al.
LEUKEMIA (2012)
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
Massimo Offidani et al.
LEUKEMIA & LYMPHOMA (2012)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L. Wolf et al.
LEUKEMIA & LYMPHOMA (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Peter A. Jones
NATURE REVIEWS GENETICS (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Brian A. Walker et al.
BLOOD (2011)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J. Harrison et al.
BLOOD (2011)
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation
Rita Shaknovich et al.
BLOOD (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma
Heidi Rye Hudlebusch et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Bromodomains as therapeutic targets
Susanne Muller et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy
Kevin D. Boyd et al.
GENES CHROMOSOMES & CANCER (2011)
NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
Alex J. Kuo et al.
MOLECULAR CELL (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Huadong Pei et al.
NATURE (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Recombination centres and the orchestration of V(D)J recombination
David G. Schatz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
被撤回的出版物: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development (Retracted article. See vol. 40, pg. 1442, 2022)
Flavia Pichiorri et al.
CANCER CELL (2010)
DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors
Bodour Salhia et al.
CANCER RESEARCH (2010)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The DAC system and associations with multiple myeloma
Enrique M. Ocio et al.
INVESTIGATIONAL NEW DRUGS (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
H. Avet-Loiseau et al.
LEUKEMIA (2010)
Polycomb Target Genes Are Silenced in Multiple Myeloma
Antonia Kalushkova et al.
PLOS ONE (2010)
Histone deacetylases and epigenetic therapies of hematological malignancies
Ciro Mercurio et al.
PHARMACOLOGICAL RESEARCH (2010)
BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells
Himabindu Ramachandrareddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Prashant Kapoor et al.
BLOOD (2009)
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma
Guanghua Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L. R. Brito et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Stepwise Activation of Enhancer and Promoter Regions of the B Cell Commitment Gene Pax5 in Early Lymphopoiesis
Thorsten Decker et al.
IMMUNITY (2009)
Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation
Jana Krejci et al.
LEUKEMIA RESEARCH (2009)
A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome
Keisuke Nimura et al.
NATURE (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
Linking DNA methylation and histone modification: patterns and paradigms
Howard Cedar et al.
NATURE REVIEWS GENETICS (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Jotin Marango et al.
BLOOD (2008)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi et al.
CANCER CELL (2008)
The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma
Tiffany Khong et al.
HAEMATOLOGICA (2008)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity
Ji-Young Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
Pax5: the guardian of B cell identity and function
Cesar Cobaleda et al.
NATURE IMMUNOLOGY (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
BE Bernstein et al.
CELL (2006)
Prevalence of monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
MA Gertz et al.
BLOOD (2005)
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma
HR Hudlebusch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
PA Croonquist et al.
ONCOGENE (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis
IV Gregoretti et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing
I Gyory et al.
NATURE IMMUNOLOGY (2004)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
P Moreau et al.
BLOOD (2002)
Share Paper
